Boston Scientific Corporation (BSX)
NYSE · Healthcare · Medical - Devices
Profile
Boston Scientific Corporation
- Exchange
- NYSE
- Ticker
- BSX
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- US
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Key facts
Boston Scientific Corporation: key facts
- Boston Scientific Corporation (NYSE: BSX) is a Medical - Devices company in the Healthcare sector.
- In fiscal 2025, Boston Scientific Corporation reported revenue of $20.1B and net income of $2.9B.
- Revenue grew 14.0% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $21.1B and net income was $3.5B.
MonkScore
Boston Scientific Corporation's MonkScore
MonkScore
MonkScore range: 40–50
as of October 2026
Sector rank: 372 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth80–90
- Profitability60–70
- Quality80–90
- Market Conviction20–30
- Safety10–20
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Boston Scientific Corporation's annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $21.1B | $20.1B | $16.7B | $14.2B | $12.7B | $11.9B |
| Gross profit | $14.8B | $13.9B | $10.3B | $8.8B | $7.7B | $7.5B |
| Operating income | $4.4B | $4.0B | $2.6B | $2.2B | $1.8B | $1.9B |
| Net income | $3.5B | $2.9B | $1.9B | $1.6B | $698.0M | $1.0B |
| Operating cash flow | $4.5B | $4.5B | $3.4B | $2.5B | $1.5B | $1.9B |
| Capital expenditure | -$904.0M | -$876.0M | -$790.0M | -$800.0M | -$612.0M | -$554.0M |
| Free cash flow | $3.6B | $3.7B | $2.6B | $1.7B | $914.0M | $1.3B |
| Total debt | $12.6B | $12.4B | $11.1B | $9.5B | $9.3B | $9.5B |
| Cash | $539.0M | $2.0B | $414.0M | $865.0M | $928.0M | $1.9B |
Revenue growth a year
- 1-year
- 19.9%
- 3-year
- 16.5%
- 4-year
- 14.0%
Compound growth between fiscal years.
Peers
Similar companies
- Tandem Diabetes Care, Inc.NASDAQ:TNDMMonkScore range: 40–50
- Butterfly Network, Inc.NYSE:BFLYMonkScore range: 50–60
- Neogen CorporationNASDAQ:NEOGMonkScore range: 50–60
- Align Technology, Inc.NASDAQ:ALGNMonkScore range: 50–60
- Tactile Systems Technology, Inc.NASDAQ:TCMDMonkScore range: 50–60
- GE HealthCare Technologies Inc.NASDAQ:GEHCMonkScore range: 50–60
- TransMedics Group, Inc.NASDAQ:TMDXMonkScore range: 50–60
- Edwards Lifesciences CorporationNYSE:EWMonkScore range: 50–60
Compare
Compare with
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.